nach oben

Erschienen in:

01.01.2024 | Review

Quality of life issues in patients with bone metastases: A systematic review

verfasst von: Thenugaa Rajeswaran, Henry C. Y. Wong, Elwyn Zhang, Samantha K. F. Kennedy, Milena Gojsevic, Hany Soliman, Vassilios Vassiliou, Dirk Rades, Pierluigi Bonomo, Shing-Fung Lee, Adrian Wai Chan, Agata Rembielak, Eva Oldenburger, Ernesto Maranzano, Stefano Pergolizzi, Joel A. Finkelstein, Jeremie Larouche, Na Zhang, Xiaojing Zhang, Gustavo N. Marta, Albert J. M. Yee, Shengji Yu, Joanne M. van der Velden, Yvette M. van der Linden, Edward Chow, On behalf of the EORTC Quality of Life Group

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Bones are frequent sites of metastatic disease, observed in 30–75% of advanced cancer patients. Quality of life (QoL) is an important endpoint in studies evaluating the treatments of bone metastases (BM), and many patient-reported outcome tools are available. The primary objective of this systematic review was to compile a list of QoL issues relevant to BM and its interventions. The secondary objective was to identify common tools used to assess QoL in patients with BM, and the QoL issues they fail to address.

Methods

A search was conducted on Ovid MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases between 1946 and 27 January 2023 with the keywords “bone metastases”, “quality of life”, and “patient reported outcomes”. Specific QoL issues in original research studies and the QoL tools used were extracted.

Results

The review identified the QoL issues most prevalent to BM in the literature. Physical and functional issues observed in patients included pain, interference with ambulation and daily activities, and fatigue. Psychological symptoms, such as helplessness, depression, and anxiety were also common. These issues interfered with patients’ relationships and social activities. Items not mentioned in existing QoL tools were related to newer treatments of BM, such as pain flare, flu-like symptoms, and jaw pain due to osteonecrosis.

Conclusions

This systematic review highlights that QoL issues for patients with BM have expanded over time due to advances in BM-directed treatments. If they are relevant, additional treatment-related QoL issues identified need to be validated prospectively by patients and added to current assessment tools.

Nur mit Berechtigung zugänglich

Tharmalingam S, Chow E, Harris K, Hird A, Sinclair E (2008) Quality of life measurement in bone metastases: A literature review. J Pain Res 1:49–58. https://doi.org/10.2147/jpr.s4572CrossRefPubMedPubMedCentral

Jiang W, Rixiati Y, Zhao B, Li Y, Tang C, Liu J (2020) Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. J Orthop Surg 28(2). https://doi.org/10.1177/2309499020915989

Clézardin P, Coleman R, Puppo M et al (2021) Bone metastasis: Mechanisms, therapies, and biomarkers. Physiol Rev 101(3):797–855. https://doi.org/10.1152/physrev.00012.2019CrossRefPubMed

Gainford MC, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 330(7494):769–773. https://doi.org/10.1136/bmj.330.7494.769CrossRefPubMedPubMedCentral

Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20):6243s–6249s. https://doi.org/10.1158/1078-0432.CCR-06-0931CrossRefPubMed

Tsukamoto S, Kido A, Tanaka Y et al (2021) Current overview of treatment for metastatic bone disease. Curr Oncol 28(5):3347–3372. https://doi.org/10.3390/curroncol28050290CrossRefPubMedPubMedCentral

Gouveia AG, Chan DCW, Hoskin PJ et al (2021) Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review. Radiother Oncol 163:55–67. https://doi.org/10.1016/j.radonc.2021.07.022CrossRefPubMed

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372:71. https://doi.org/10.1136/bmj.n71CrossRef

Veritas Health Innovation (2023) Covidence systematic review software. http://www.covidence.org. Accessed 29 Jan 2023

10.

Coward DD, Wilkie DJ (2000) Metastatic bone pain. Meanings associated with self-report and self-management decision making. Cancer Nursing 23(2):101–108. https://doi.org/10.1097/00002820-200004000-00005CrossRefPubMed

11.

Martin M, Bell R, Bourgeois H et al (2012) Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 18(17):4841–4849. https://doi.org/10.1158/1078-0432.CCR-11-3310CrossRefPubMed

12.

Agarwal KK, Singla S, Arora G, Bal C (2015) (177) Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: A phase II study. Eur J Nucl Med Mol Imaging 42(1):79–88. https://doi.org/10.1007/s00259-014-2862-zCrossRefPubMed

13.

Bongiovanni A, Recine F, Fausti V et al (2019) Ten-year experience of the multidisciplinary osteoncology center. Support Care Cancer 27(9):3395–3402. https://doi.org/10.1007/s00520-019-4635-5CrossRefPubMed

14.

Gater A, Abetz-Webb L, Battersby C et al (2011) Pain in castration-resistant prostate cancer with bone metastases: A qualitative study. Health Qual Life Outcomes 9:88. https://doi.org/10.1186/1477-7525-9-88CrossRefPubMedPubMedCentral

15.

Chow E, Fan G, Hadi S, Filipczak L (2007) Symptom clusters in cancer patients with bone metastases. Support Care Cancer 15(9):1035–1043. https://doi.org/10.1007/s00520-007-0241-zCrossRefPubMed

16.

Shi Z, Qiu H, Yu S (2010) The investigation of symptoms burden and treatment status in patients with bone metastasis. Chin Ger J Clin Oncol 9(2):63–67. https://doi.org/10.1007/s10330-010-0009-7CrossRef

17.

Gottwald L, Dukowicz A, Misiewicz B, Pasz-Walczak G, Cialkowska-Rysz A (2011) An extremely rare presentation of relapse in endometrioid endometrial adenocarcinoma: Isolated metastases to the tibia and humerus. Case report and review of the literature. Eur J Gynaecol Oncol 32(5):547–550PubMed

18.

Plancarte R, Guajardo J, Meneses-Garcia A et al (2014) Clinical benefits of femoroplasty: A nonsurgical alternative for the management of femoral metastases. Pain Physician 17(3):227–234CrossRefPubMed

19.

Moinpour C, Savage M, Troxel A et al (1998) Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial. JNCI 90(20):1537–1544. https://doi.org/10.1093/jnci/90.20.1537CrossRefPubMed

20.

Lindqvist O, Rasmussen BH, Widmark A (2008) Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. Eur J Oncol Nurs 12(4):283–290. https://doi.org/10.1016/j.ejon.2008.03.003CrossRefPubMed

21.

Kim Y, Krishnan CK, Kim HS, Cho HS, Han I (2020) Ambulation recovery after surgery for metastases to the femur. Oncologist 25(1):e178–e185. https://doi.org/10.1634/theoncologist.2019-0107CrossRefPubMed

22.

Charles T, Ameye L, Gebhart M (2017) Surgical treatment for periacetabular metastatic lesions. Eur J Surg Oncol 43(9):1727–1732. https://doi.org/10.1016/j.ejso.2017.03.018CrossRefPubMed

23.

Antal I, Szoke G, Szendroi M et al (2023) Functional outcome and quality of life following resection of the proximal humerus performed for musculoskeletal tumors and reconstruction done by four different methods. Musculoskelet Surg. https://doi.org/10.1007/s12306-022-00771-wCrossRefPubMedPubMedCentral

24.

Porter AT, McEwan AJ, Powe JE et al (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25(5):805–813. https://doi.org/10.1016/0360-3016(93)90309-jCrossRefPubMed

25.

Harris K, Chow E, Zhang L et al (2009) Patients’ and health care professionals’ evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 45(14):2510–2518. https://doi.org/10.1016/j.ejca.2009.05.024CrossRefPubMed

26.

Torvik K, Holen J, Kaasa S et al (2008) Pain in elderly hospitalized cancer patients with bone metastases in Norway. Int J Palliat Nurs 14(5):238–245. https://doi.org/10.12968/ijpn.2008.14.5.29491CrossRefPubMed

27.

Akakura K, Uemura H, Miyazaki K et al (2021) A qualitative research study in Japan investigating patients’ experience with metastatic castration-resistant prostate cancer: From diagnosis to decision for Ra-223 treatment. Future Oncol 17(36):5103–5118. https://doi.org/10.2217/fon-2021-0773CrossRefPubMed

28.

van der Doelen MJ, Oving IM, Wyndaele DNJ et al (2022) Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. Prostate Cancer Prostatic Dis 26:142–150. https://doi.org/10.1038/s41391-022-00569-8CrossRefPubMedPubMedCentral

29.

Chen JJ, Roldan CS, Nichipor AN et al (2021) Patient-provider communication, decision-making, and psychosocial burdens in palliative radiotherapy: A qualitative study on patients’ perspectives. J Pain Symptom Manage 62(3):512–522. https://doi.org/10.1016/j.jpainsymman.2021.01.129CrossRefPubMed

30.

Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR (1998) Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 47(3):233–240. https://doi.org/10.1016/s0167-8140(98)00011-5CrossRefPubMed

31.

Laitinen M, Nieminen J, Pakarinen TK (2011) Treatment of pathological humerus shaft fractures with intramedullary nails with or without cement fixation. Arch Orthop Trauma Surg 131(4):503–508. https://doi.org/10.1007/s00402-010-1172-6CrossRefPubMed

32.

Katzer A, Meenen NM, Grabbe F, Rueger JM (2002) Surgery of skeletal metastases. Arch Orthop Trauma Surg 122(5):251–258. https://doi.org/10.1007/s00402-001-0359-2CrossRefPubMed

33.

Amadori D, Aglietta M, Alessi B et al (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663–670. https://doi.org/10.1016/S1470-2045(13)70174-8CrossRefPubMed

34.

Parker CC, Pascoe S, Chodacki A et al (2013) A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63(2):189–197. https://doi.org/10.1016/j.eururo.2012.09.008CrossRefPubMed

35.

Napoli A, De Maio A, Alfieri G et al (2023) Focused Ultrasound and External Beam Radiation Therapy for Painful Bone Metastases: A Phase II Clinical Trial. Radiology 307(2). https://doi.org/10.1148/radiol.211857

36.

Fares A, Shaaban MH, Reyad RM, Ragab AS, Sami MA (2018) Combined percutaneous radiofrequency ablation and cementoplasty for the treatment of extraspinal painful bone metastases: A prospective study. J Egypt Natl Canc Inst 30(3):117–122. https://doi.org/10.1016/j.jnci.2018.05.002CrossRefPubMed

37.

Sahgal A, Myrehaug SD, Siva S et al (2021) Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: An open label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol 22(7):1023–1033. https://doi.org/10.1016/S1470-2045%2821%2900196-0CrossRefPubMed

38.

Pielkenrood BJ, van der Velden JM, van der Linden YM et al (2021) Pain response after stereotactic body radiation therapy versus conventional radiation therapy in patients with bone metastases - A phase 2 randomized controlled trial within a prospective cohort. Int J Radiat Oncol Biol Phys 110(2):358–367. https://doi.org/10.1016/j.ijrobp.2020.11.060CrossRefPubMed

39.

Chow E, Hird A, Velikova G et al (2009) The European organisation for research and treatment of cancer quality of life questionnaire for patients with bone metastases: The EORTC QLQ-BM22. Eur J Cancer 45(7):1146–1152. https://doi.org/10.1016/j.ejca.2008.11.013CrossRefPubMed

40.

Broom R, Du H, Clemons M et al (2009) Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: Measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain. J Pain Symptom Manage 38(2):244–257. https://doi.org/10.1016/j.jpainsymman.2008.08.005CrossRefPubMed

41.

Barnadas A, Muñoz M, Margelí M et al (2019) BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study. J Patient Rep Outcomes 3(1):72. https://doi.org/10.1186/s41687-019-0161-yCrossRefPubMedPubMedCentral

42.

Cleeland CS, Gonin R, Hatfield AK et al (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592–596. https://doi.org/10.1056/NEJM199403033300902CrossRefPubMed

43.

Rogowski P, Trapp C, von Bestenbostel R et al (2021) Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol 16:125. https://doi.org/10.1186/s13014-021-01849-8CrossRefPubMedPubMedCentral

44.

Wheelwright S, Bjordal K, Bottomley A et al (2021) EORTC quality of life group guidelines for developing questionnaire modules. Fifth edition. https://www.eortc.org/app/uploads/sites/2/2022/07/Module-Guidelines-Version-5-FINAL.pdf. Accessed 29 Jan 2023

45.

Zaza C, Baine N (2002) Cancer pain and psychosocial factors: A critical review of the literature. J Pain Symptom Manage 24(5):526–542. https://doi.org/10.1016/S0885-3924(02)00497-9CrossRefPubMed

46.

Coleman R, Hadji P, Body JJ et al (2020) Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 31(12):1650–1663. https://doi.org/10.1016/j.annonc.2020.07.019CrossRefPubMed

47.

de Vries S, Lormans T, de Graaf E, Leget C, Teunissen S (2021) The content validity of the items related to the social and spiritual dimensions of the Utrecht Symptom Diary-4 Dimensional from a patient’s perspective: A qualitative study. J Pain Symptom Manage 61(2):287-294.e2. https://doi.org/10.1016/j.jpainsymman.2020.07.036CrossRefPubMed

Titel: Quality of life issues in patients with bone metastases: A systematic review
verfasst von: Thenugaa Rajeswaran
Henry C. Y. Wong
Elwyn Zhang
Samantha K. F. Kennedy
Milena Gojsevic
Hany Soliman
Vassilios Vassiliou
Dirk Rades
Pierluigi Bonomo
Shing-Fung Lee
Adrian Wai Chan
Agata Rembielak
Eva Oldenburger
Ernesto Maranzano
Stefano Pergolizzi
Joel A. Finkelstein
Jeremie Larouche
Na Zhang
Xiaojing Zhang
Gustavo N. Marta
Albert J. M. Yee
Shengji Yu
Joanne M. van der Velden
Yvette M. van der Linden
Edward Chow
On behalf of the EORTC Quality of Life Group
Publikationsdatum: 01.01.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 1/2024
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-023-08241-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Quality of life issues in patients with bone metastases: A systematic review